Hints and tips:
Related Special Reports
...Dunoyer was AstraZeneca’s chief financial officer when it took the unusual move of raising more funds — $3.5bn — on the public market to contribute towards a $5.5bn partnership with Daiichi Sankyo....
...Enhertu, backed by UK’s AstraZeneca and Japan’s Daiichi Sankyo, has also received FDA approval. It will be years before Gilead might recoup its cost. At worst, the deal could go the way of Kite....
...It would follow in the footsteps of a recent deal between AstraZeneca and the Japanese pharmaceutical Daiichi Sankyo to develop and market an antibody drug conjugate called DS-1062 for lung and breast cancer...
...AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal...
...R&D spend was also higher, but the annualisation of a step-up in costs for the Daiichi Sankyo deal ends during this year. So the underlying margin seems better than it looks....
...A recent $3.5bn equity placement, to part-fund a collaboration with Japan’s Daiichi Sankyo on an experimental treatment for breast cancer, had been “dilutive” of the company’s shares, which ended Tuesday...
...They previously came to international attention with the $4.7bn sale of Ranbaxy, their drugs company, to Daiichi Sankyo of Japan....
Treasury bonds, yen and gold gain ground
...Daiichi Sankyo, a manufacturer of hypertension and other prescription drugs, which sees 28 per cent of its revenue coming from North America, slipped 1.2 per cent....
...The index has analysed the industry’s research and development pipeline, including the big four and four other challengers (Johnson & Johnson, Daiichi Sankyo, Takeda and Serum Institute of India)....
...It was at the Arms Park in 1973 that Gareth Edwards scored a try for the Barbarians v the All Blacks, which experts say has never been matched....
...For Daiichi Sankyo, the $5bn purchase of Ranbaxy in 2008 in India ended badly with a sale this year following regulatory setbacks caused by quality issues....
...Sankyo agreed to buy Daiichi Pharmaceutical the same year. These deals created respectively the third and fourth biggest players....
...Daiichi Sankyo’s 2008 takeover of India’s Ranbaxy has long seemed destined to join the list of Japan’s worst overseas purchases – a line-up populated with deals such as Nomura’s buyout of parts of Lehman...
...Last month, drugmaker Daiichi Sankyo ended its disastrous tie-up with generics producer Ranbaxy....
...Efforts by pharma groups to expand abroad, including Daiichi Sankyo’s disastrous $4.7bn acquisition of Ranbaxy, an Indian generics maker, have not inspired confidence....
...That is a far cry from 2005, when giant deals such as the $7bn Daiichi/Sankyo drugs merger pushed the domestic share to 80 per cent, raising hopes that more idle capacity would be shaken out....
...Drugmaker Daiichi Sankyo returned to the bond markets for the first time in four years this month, citing a favourable market environment....
...One year later, drugmaker Daiichi Sankyo took a $3.9bn writedown just months after taking control of generics manufacturer Ranbaxy Laboratories – one of the largest foreign deals involving an Indian company...
...Daiichi Sankyo, a drugmaker, was forced to take a Y359bn writedown in 2009 within months of buying Indian generic drugs group Ranbaxy after its share price plunged in the face of problems with US regulators...
...Drugmaker Daiichi Sankyo, for example, stuck to its offer price for India’s Ranbaxy even as the target’s stock plunged after the Lehman shock, and as the Indian drugmaker faced a US import ban....
...Daiichi Sankyo, Japan’s third-biggest drugmaker, gained 2.9 per cent to Y1,544 after announcing a tie-up with Britain’s GlaxoSmithKline to develop vaccines for the Japanese market....
...His comments contrast with rival Japanese drug companies such as Daiichi Sankyo and Takeda, which have expanded into generic medicine and spread their footprint into Europe and emerging markets in the past...
...Takeda’s acquisition followed the lead of Daiichi Sankyo, which purchased Ranbaxy of India in 2008 as a way to diversify into emerging markets and off patent medicines, as well as strengthening its expertise...
...Ranbaxy, a unit of Japan’s Daiichi Sankyo that had global sales of nearly $1.9bn last year, was the first to apply for FDA approval in 2002, but was held up over violations at a plant in India....
International Edition